Insights from 2024 SGO Annual Meeting


 

SGO 2024 Insights: "Final OS Data of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Pts With Recurrent Platinum-Resistant Ovarian Cancer"

258 views
March 26, 2024
Comments 0
Login to view comments. Click here to Login